Lilly to acquire Kelonia Therapeutics for $3.25 billion to advance in vivo CAR-T cell therapies
On Apr. 20, 2026, Eli Lilly and Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery,…
On Apr. 20, 2026, Eli Lilly and Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery,…
On Mar. 12, 2026, Mass General Brigham (MGB) announced it has received a $50 million gift that will…